Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00440518
Other study ID # SP0906
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date February 2007
Est. completion date July 2008

Study information

Verified date July 2017
Source UCB Pharma
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to see how safe and effective Lacosamide (LCM) is when taken by mouth, twice a day for up to 18 weeks to prevent migraines.


Description:

This study is for subjects who have been diagnosed with migraine for at least one year and who are currently taking an effective abortive medication(s).


Recruitment information / eligibility

Status Completed
Enrollment 218
Est. completion date July 2008
Est. primary completion date July 2008
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- History of migraines headaches for 1 year and well documented 3 month retrospective history of migraines.

- Experience 2-8 migraines per month but not more than 15 headache days per month. There should be at least 48 hours of freedom between headaches.

- On effective stable abortive medication(s) for the acute treatment of migraine.

Exclusion Criteria:

- Subject in another investigational drug or device study within the last 30 days or is currently in another investigational drug trial.

- Use of triptans or ergots for migraine abortive treatment > 2-3 days per calendar week 2 months prior to screening.

- Experience 15 or more headache days per month of any kind 2 months prior to screening.

- Has another consistent or chronic form of headache.

- Unable to stop medications, herbs, vitamins, or minerals used to prevent a migraine from occurring.

- Pregnant or nursing women and those of child bearing potential who are not surgically sterile, or 2 years post menopausal, or do not practice 2 combined methods of birth control, unless sexually abstinent, during the trial.

- Significant laboratory or electrocardiograms (ECG) abnormalities

- Significant medical history including cardiovascular abnormalities.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lacosamide
Lacosamide 100mg immediate-release film-coated tablet (white,oval) oral administration twice daily 12 hours apart
Other:
Placebo
Immediate-release film coated tablet (white, oval), oral administration twice daily 12 hours apart
Drug:
Lacosamide
Lacosamide 300mg, immediate-release film coated tablet (white,oval), oral administration twice daily 12 hours apart.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
UCB Pharma

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in Mean Migraine Headache Rates During the Entire 14-week Maintenance Period Baseline, Entire 14-week Maintenance Period
Secondary Change From Baseline in Mean Migraine Headache Rates During the Last 4 Weeks of the Maintenance Period Baseline, last 4 weeks of the 14-week Maintenance Period
Secondary Number of Subjects Who Experience a 50 Percent or Greater Reduction From Baseline in Migraine Frequency During the Entire 14-week Maintenance Period. Baseline, Entire 14-week Maintenance Period
Secondary Number of Subjects Who Experience a 50 Percent or Greater Reduction From Baseline in Migraine Frequency During the Last 4 Weeks of the Maintenance Period. Baseline, last 4 weeks of the 14-week Maintenance Period
Secondary Changes From Baseline in Improvement of Function and Reduction of Disability Using the Headache Impact Test (HIT-6) Headache Impact Test (HIT-6™) consists of 6 items designed to measure the impact headaches have on a person's ability to function. Scores from the 6 questions will be added to create a total score. Range of the total score is 36 to 78. Higher scores indicate a greater impact on the subject's quality of life. Baseline, last visit in the 17-week Trial Period
See also
  Status Clinical Trial Phase
Completed NCT05525611 - Cabergoline as a Preventive Treatment for Chronic Migraine N/A
Completed NCT06192173 - Patent Foramen Ovale Closure in Migraine
Recruiting NCT03832998 - Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine Phase 3
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Not yet recruiting NCT06428838 - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context Phase 3
Completed NCT06304675 - Manageable Environmental Factors in Migraine
Completed NCT04084314 - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study Phase 4
Recruiting NCT05517200 - Pilot Study for a Machine Learning Test for Migraine
Completed NCT04179474 - Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine Phase 1
Recruiting NCT04603976 - Registry for Migraine - Clinical Core Phase 4
Completed NCT03597529 - CHOCOlate MeLatonin for AdolescenT MigrainE Phase 2
Completed NCT04197349 - Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman Phase 1
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Active, not recruiting NCT05064371 - Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan Phase 3
Suspended NCT04069572 - Vibratory Stimulation for the Treatment of Chronic Pain N/A
Not yet recruiting NCT04859374 - Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach N/A
Not yet recruiting NCT03083860 - Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions. N/A
Completed NCT02905227 - A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder Phase 1
Enrolling by invitation NCT02532023 - The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients Phase 4
Completed NCT02108678 - One-Day Intervention for Depression and Impairment in Migraine Patients N/A